BRIEF published on 03/14/2025 at 07:35, 1 year 3 months ago Sensorion : Bilan 2024 et Perspectives pour 2025 Résultats Financiers Investissements Thérapies Géniques SENS-401 SENS-501
BRIEF published on 03/14/2025 at 07:35, 1 year 3 months ago Sensorion: 2024 Review and Outlook for 2025 Financial Results Investments SENS-401 SENS-501 Gene Therapies
PRESS RELEASE published on 03/14/2025 at 07:30, 1 year 3 months ago Informations privilégiées / Communiqué sur comptes, résultats Sensorion présente ses résultats financiers pour l’exercice 2024, fait le point sur ses activités et annonce la mise à disposition du rapport annuel. Renforcement financier, essais cliniques avancés Résultats Financiers Innovation Scientifique Thérapie Génique Études Cliniques Sensorion
PRESS RELEASE published on 03/14/2025 at 07:30, 1 year 3 months ago Inside Information / News release on accounts, results Sensorion reports full-year 2024 results and provides corporate update with significant milestones achieved in gene therapy clinical trials and financial highlights. Company well positioned for growth in 2025 Clinical Trials Financial Highlights Gene Therapy Full-year Results Sensorion
BRIEF published on 03/07/2025 at 07:35, 1 year 3 months ago Sensorion conclut le recrutement pour l'essai NOTOXIS sur le SENS-401 Essai Clinique Sensorion SENS-401 Cisplatine Ototoxicité
BRIEF published on 03/07/2025 at 07:35, 1 year 3 months ago Sensorion Completes Recruitment for NOTOXIS Trial of SENS-401 Clinical Trial Sensorion SENS-401 Cisplatin Ototoxicity
PRESS RELEASE published on 03/07/2025 at 07:30, 1 year 3 months ago Informations privilégiées / Autres communiqués Sensorion annonce la fin du recrutement des patients dans NOTOXIS, essai clinique Phase 2a SENS-401 pour prévenir ototoxicité cisplatine. Résultats NOTOXIS attendus fin 2025 Phase 2a Sensorion SENS-401 Ototoxicité NOTOXIS
PRESS RELEASE published on 03/07/2025 at 07:30, 1 year 3 months ago Inside Information / Other news releases Sensorion completes patient enrollment in NOTOXIS Phase 2a Clinical Trial of SENS-401 for Cisplatin-Induced Ototoxicity prevention, targeting a significant unmet medical need Clinical Trial Sensorion SENS-401 NOTOXIS Cisplatin-Induced Ototoxicity
BRIEF published on 02/21/2025 at 07:35, 1 year 3 months ago Sensorion's SENS-501 Clinical Trial Progresses with Positive DMC Recommendation Gene Therapy Clinical Trial Sensorion Hearing Loss SENS-501
BRIEF published on 02/21/2025 at 07:35, 1 year 3 months ago L'essai clinique SENS-501 de Sensorion progresse avec une recommandation DMC positive Essai Clinique Thérapie Génique Sensorion Perte Auditive SENS-501
Published on 06/19/2026 at 04:30, 9 hours 59 minutes ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 13 hours 9 minutes ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 13 hours 22 minutes ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/19/2026 at 00:00, 14 hours 29 minutes ago Redwood AI Announces Initiation of Chemical Risk Assessment Module
Published on 06/19/2026 at 14:13, 15 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/19/2026 at 13:54, 34 minutes ago Agenda items receive broad approval at the annual general meeting; Jan Oberbeck re-elected to the Supervisory Board
Published on 06/19/2026 at 12:20, 2 hours 8 minutes ago CGTN: China, Myanmar agree to deepen pragmatic cooperation across the board
Published on 06/19/2026 at 12:06, 2 hours 23 minutes ago Schaeffler and Delair scale European drone production
Published on 06/19/2026 at 11:47, 2 hours 42 minutes ago Fuller, Smith & Turner PLC: TR-1: Standard form for notification of major holdings
Published on 06/19/2026 at 08:55, 5 hours 34 minutes ago ALPOU - Groupe POULAILLON - Communiqué mise à disposition de la note d'information et DAI relatif à la société visée
Published on 06/19/2026 at 08:55, 5 hours 34 minutes ago ALPOU - Groupe POULAILLON - Communiqué mise à disposition de la note d'information et DAI relatif à EUGENIE
Published on 06/19/2026 at 08:49, 5 hours 40 minutes ago Groupe DLSI - Evolution de la gouvernance et recomposition du Directoire
Published on 06/18/2026 at 18:00, 20 hours 29 minutes ago Publication du nombre d’actions composant le capital et du nombre total de droits de vote au 31 mai 2026
Published on 06/18/2026 at 18:00, 20 hours 29 minutes ago Outstanding shares and voting rights statement at 31 May 2026
